EUSA Pharma has appointed Lee Morley to be its new chief executive officer, taking over from Bryan Morton who becomes the UK specialty pharmaceutical company’s executive chairman.
Morton originally founded EUSA in 2005, leading it until its 2012 acquisition by Jazz Pharmaceuticals for $700m and then taking the reins again last month when EUSA was once again launched as a new business with five specialty hospital products from Jazz.
EUSA’s new CEO Morley comes to the company from Jazz, where he was vice president, head of commercial for Europe and International Markets, with responsibility for the original EUSA Pharma business.
Prior to his time with Jazz, and before that the pre-acquisition EUSA business, Morley was director of sales effectiveness at specialty oncology and critical care company Zeneus Pharma.
Before that he held a number of sales and marketing management positions at Merck, Sharp and Dohme, including UK National Sales Manager.
Meanwhile, EUSA has also added industry veteran and Novo Nordisk chairman Dr Göran Ando to its board of directors.
Commenting on the appointments Bryan Morton said: “We are delighted to welcome both Lee and Göran to EUSA Pharma during this exciting time in the development of the company.
“We have highly ambitious growth plans to build EUSA into a world-class specialty pharma business through acquisition and in-licensing, and Lee’s extensive commercial experience will prove invaluable in helping us achieve our goal. We also welcome the strategic insight and direction Göran will provide as we transform the business.”